Fleming Gulf announced its BioProcess Asia Pacific Conference, scheduled to take place from 26th to 28th July 2010 in Singapore. Because there is growing at a very high rate more than other regions, though Asia Pacific profit share of Biopharmaceutical Industry accounts to 3.3% by share.
With most of the pharmaceutical companies establishing biotechnology as an integral part of their business strategy in the near future, and acquiring or developing expertise in select technologies such as recombinant DNA, the country is a strong contender for the biopharmaceutical / biogenerics market.
Forming of strategic alliances and increase in international collaboration lead to the high growth of biopharmaceutical market in Asia Pacific. This is creating a strong need for production of biopharmaceuticals at higher Qualities and Volumes as well as developing an effective and efficient bioprocess.
The Biopharma manufacturing is supported by Government Initiatives and the up-to-date trend – Outsourcing of the production of Biopharmaceutical companies to Asia Pacific – minimize the costs of the whole Biopharmaceutical process.
Based on this emerges some crucial topics which needs to be discussed on the top level platform. The understanding of the strategies to create flexible facility and forecasting future requirements as well as exploring Biosimilars challenges and regulatory models and operational excellence will be discussed by world wide experts at the BioProcess Asia Conference.